John Sourbeer
Stock Analyst at UBS
(0.95)
# 3,936
Out of 5,128 analysts
44
Total ratings
42.86%
Success rate
-14.44%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $10.66 | +17.26% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $150.14 | -20.07% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $278.44 | +27.50% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $47.31 | +5.69% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $202.92 | +18.27% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $21.77 | +7.95% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $33.37 | +34.85% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $2.13 | -6.10% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $613.09 | -21.71% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $53.01 | +92.42% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $19.99 | +150.13% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $127.04 | +0.76% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $10.66
Upside: +17.26%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $150.14
Upside: -20.07%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $278.44
Upside: +27.50%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $47.31
Upside: +5.69%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $202.92
Upside: +18.27%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $21.77
Upside: +7.95%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $33.37
Upside: +34.85%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $2.13
Upside: -6.10%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $613.09
Upside: -21.71%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $53.01
Upside: +92.42%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $19.99
Upside: +150.13%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $127.04
Upside: +0.76%